A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Sodium Polystyrene Sulfonate (Kionex)

Potassium Binder class · 9 generic manufacturers · 13 ANDAs filed at FDA.

First FDA approval1982-12-08
Generic availableYes · 9 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$4.5M in CY2024 Part D spend78K claims · 47K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.097/unit
9 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.271
Across all dosage forms in distribution.
Highest NADAC
$0.437
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema12 entries indexed · 4 visible
What is Sodium Polystyrene Sulfonate used for?

Sodium Polystyrene Sulfonate is a Potassium Binder medication tracked in Medicare Part D.

Is there a generic for Sodium Polystyrene Sulfonate?

Yes. 13 ANDAs filed at FDA, 9 generic manufacturers currently shipping.

How much does my plan pay for Sodium Polystyrene Sulfonate?

Across 329 Part D plans, Sodium Polystyrene Sulfonate averages $0.271/unit (NADAC). Lowest available: $0.097/unit. Highest in distribution: $0.437/unit.

Is Sodium Polystyrene Sulfonate on the FDA shortage list?

No. Sodium Polystyrene Sulfonate is not currently on the FDA Drug Shortage Database.

8 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Potassium Binder1 alternative in D1
01
Patiromer
Brand: VELTASSA
$34.02Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (9 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.